How Long Do You Need to Use Wegovy to See Results — and Stay There

Step 1: the titration phase, your body adjusting, not yet losing much

Wegovy treatment does not start at full therapeutic strength. The licensed schedule begins at 0.25 mg weekly and moves up through 0.5 mg, 1.0 mg and 1.7 mg before reaching the standard 2.4 mg maintenance dose, with roughly a month at each level. The 7.2 mg dose approved by the MHRA in January 2026 follows the same graduated path, extending it further. This titration period typically takes four to five months. During it, meaningful weight loss is possible but modest, the dose is building tolerance, not yet exerting its full appetite-reducing effect. Patience during this phase is clinically important: people who push through early side effects and complete titration tend to see much better outcomes. How quickly Wegovy begins to work is a separate question from how long you need to stay on it, though the two are closely connected. The Wegovy overview covers the mechanism in more detail if you want the fuller picture before reading on.

Step 2: the maintenance phase, where the 68-week evidence lives

A question our prescribers hear most weeks is some version of: "Can I just use it for a few months and then stop?" The clinical evidence suggests that approach misses most of the benefit. The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity or overweight for 68 weeks. Those on 2.4 mg semaglutide lost around 15% of their body weight on average, but that average was built across the full 68 weeks, with weight loss continuing to accumulate well beyond the early months. Stopping before maintenance is properly established cuts that curve short. How long treatment tends to run depends partly on how your body responds and partly on the clinical review at six months. Under NICE's appraisal of semaglutide (TA875), if you have not achieved at least 5% weight loss after six months on the maintenance dose, continuing is reviewed. This is not a punishment clause, it is a checkpoint to make sure treatment is doing its job for you specifically.

Step 3: the long-term question, what happens when you stop, and who should stay on it?

The most important thing to understand about Wegovy's duration is what the stopping data shows. A follow-up study to STEP 1 found that participants who discontinued semaglutide regained most of their lost weight within a year, without maintaining equivalent lifestyle changes. This is consistent with the current understanding of obesity as a condition shaped by biology, not simply by choices, the medicine works partly by resetting appetite signals, and those signals tend to reassert themselves when the medicine is withdrawn. That is why the decision to stop should be made with a prescriber rather than independently. Within the NHS, NICE's recommendation caps semaglutide at two years within a specialist setting. Private prescribing is governed by the licensed indication and individual clinical assessment, there is no automatic two-year ceiling in private practice, but each repeat order should involve a genuine clinical review. At nume, every repeat prescription is reviewed before it is issued; nothing auto-renews. If you are curious about how long it is safe to continue, that is exactly the kind of question our prescribers discuss at review.

What this means practically: planning your treatment timeline

Working backwards from the evidence: allow four to five months for titration, then expect the core treatment phase to run to at least 68 weeks total. Add the review at six months of maintenance. If you are considering Wegovy and wondering whether it fits around a specific life event or timeline, be honest about that with your prescriber from the start, it changes what "success" looks like and how progress gets reviewed. Cost across those months is a real consideration; the Wegovy price comparison page sets out what private treatment typically costs in the UK and what the price should include. The broader context of weight-loss treatment options is worth reviewing too, particularly if you are weighing Wegovy against tirzepatide or other approaches. If you are ready to find out whether you are clinically suitable, check your eligibility with our prescribers, the consultation is free, and a real clinician reviews your answers the same day.